|Day Low/High||0.33 / 0.34|
|52 Wk Low/High||0.06 / 0.21|
Financials for Second Quarter Ended June 30, 2017 will be released on August 14, 2017
Advocacy Organization to Work with Health Canada with the Goal to Gain Approval
Cytokine Signatures Could Lead to the First Empirical Measure of Disease Severity in Chronic Fatigue Syndrome
12 Pancreatic Cancer Patients Receiving Ampligen® Immuno-Oncology Therapy in Early Access Program
Joseph C. Horvath, M.D., Named Deputy Chief Medical Officer to Oversee Ampligen European Pancreatic Cancer Programs
Promotes Carol Smith, Ph.D., to Chief Manufacturing Officer and Deputy Chief Scientific Officer
The company has generated revenues from the lots of newly manufactured Ampligen
First patient treated in the Netherlands
TheStreet's biotech columnist offers his own report card on biotech stocks.
Conference Call Scheduled for Tuesday, November 15, 2016 at 11:00 AM EST
Recent Articles on Hemispherx Biopharma by BioWorld and Pink Sheet Posted to Corporate Website
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.